← Return to Video Q&A about Amyloidosis – What Patients Need to Know
Event
Video Q&A about Amyloidosis – What Patients Need to Know
Event Date: June 4, 2015 | 12:00pm - 1:00pm ET
Comment receiving replies
Replies to "Is there any research on treating AL Amyloidosus with velcade only without the accompanying use of..."
Connect

The mature and updated results of CAN2007, a phase 1/2 study of once- and twice-weekly single-agent bortezomib in relapsed AL amyloidosis by Donna Reece et al. were published in the journal Blood in 2014. Seventy patients were treated and single-agent bortezomib produced durable hematologic responses and promising long-term overall survival. This trial was registered at http://www.clinicaltrials.gov as #NCT00298766.